Table 4 Safety analysis after treatment at 4–6 weeks post-treatment
From: Acceptability and safety of thermal ablation to prevent cervical cancer in sub-Saharan Africa
Side effects | Number | Percent |
|---|---|---|
Watery dischargea (n = 197) | ||
Grade 0 | 48 | 24.5 |
Grade 1 | 149 | 75.5 |
Grade 2–4 | 0 | 0 |
Days with watery discharge (n = 137) (mean ± SD) | 13.1 ± 7.8 | |
Bloody-stained discharge b (n = 196) | ||
Grade 0 | 154 | 78.5 |
Grade 1 | 42 | 21.5 |
Grade 2–4 | 0 | 0 |
Days with bleeding (n = 34) (mean ± SD) | 10.8 ± 8.9 | |
Malodorous discharge, purulent discharge b (n = 197) | ||
Grade 0 | 168 | 85.5 |
Grade 1 | 29 | 14.5 |
Grade 2–4 | 0 | 0 |
Days of malodorous/purulent discharge (n = 25) | 10.9 ± 8.3 | |
Posttreatment bleeding requiring treatment (n = 196) | ||
Grade 0 | 195 | 99.5 |
Grade 1 | 1 | 0.5 |
Grade 2–4 | 0 | 0 |
Pain when urinating b (n = 196) | ||
Grade 0 | 192 | 98 |
Grade 1 | 4 | 2 |
Grade 2–4 | 0 | 0 |
Days with pain when urinating (n = 3) (mean ± SD) | 4.3 ± 2.3 | |
Infection (n = 197) | ||
Grade 0 | 189 | 97 |
Grade 1 | 0 | 0 |
Grade 2 | 6 | 3 |
Grade 3–4 | 0 | 0 |
Days with infection treated with antibiotics (n = 6) (mean ± SD) | 7.3 ± 4.0 | |
Emergency consultation n = 196 | ||
Grade 0 | 196 | 100 |
Grade 1–4 | 0 | 0 |